Takeda inks a licensing deal with Keros for elritercept, a late-stage anemia drug, and plans a Phase 3 trial in ...

The U.S. Food and Drug Administration has approved a drug developed at Stanford Medicine that offers hope to people diagnosed ...

Keros’ elritercept has shown promising efficacy signals in myelofibrosis and myelodysplastic syndromes and could pose a ...

Millions of us take vitamins, minerals, and other supplements daily to improve our health and well-being—but taking certain ...

Outcomes study will assess mortality and hospitalization in patients treated with Vafseo compared to current standard of care "We look forward to begin treating CKD anemia patients on dialysis with ...

Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, ...

The outlay, plus up to $1.1 billion in milestones, has secured Takeda ex-China rights to a molecule that could compete with ...

The daily tablet can help reduce pain and inflammation caused by the chronic and often debilitating condition.

The 2023 AABB guidelines overall favor a restrictive transfusion strategy, recommending RBC transfusion for hemoglobin <7 ...

For people with the bleeding disorder hemophilia, life can seem like one continuous state of alertness. If they accidentally ...

Sotagliflozin, a dual SGLT1/2 inhibitor, increased hemoglobin levels in patients with type 2 diabetes and chronic kidney ...